Htai 2019 Abstract Book
Total Page:16
File Type:pdf, Size:1020Kb
HTA Beyond 2020: Ready For The New Decade? ABSTRACT BOOK Contents Oral Presentations 14 OP01 Building Control Arms For Cancer Clinical Trials From Real-World Data 14 OP02 Matching Methods In Precision Oncology: An Introduction And Example 14 OP03 Patient Survival From Non-Small Cell Lung Cancer (1973-2013) 15 OP04 Real Biased Evidence? Comparing “Real World” Mortality Data And RCTs 16 OP05 Systematic Review Of Effectiveness Of Systems Approaches In Healthcare 17 OP06 Evaluating Public Health Interventions: A Neglected Area In HTA Field 18 OP07 Developing A Decision Tool For Selecting Approaches For Rapid Reviews 19 OP08 MCDA For HTA: Which Agenda To Address Methodological Challenges? 20 OP09 Analysis Of Medical Devices Studies For Market Access In Europe 21 OP10 Approaches To Gain Reimbursement For Medical Devices In Germany 21 OP11 Could Early Dialogues In Medical Devices Accelerate Reimbursement? 22 OP12 PLEG In Europe: From National Practices To Cross-Border Collaboration 23 OP13 Cost Analysis Of Neonatal Tele-Homecare Compared To In-Hospital Care 24 OP14 Progress In Use Of Telerehabilitation For Persons With COPD 25 OP15 Use Of Digital Health Information Among HIV Populations In Uganda 26 OP16 Assessing The Viability Of Medical Equipment Procurement In Hospital 27 OP18 A Case Study Of Local Context-Dependent Decision Making In HTA 27 OP19 Does The HST Represent A Best Practice Model For Ultra-Orphan HTA? 28 OP20 Has The New HST Process Improved The Recommendation Chance In England? 29 OP21 Enhancing Capability: Patient Impact In Ultra-Orphan Conditions 30 OP22 Patient-Based Evidence: Its Role In Decision Making On New Medicines 31 OP23 Smart Searches For Context-Sensitive Topics: Geographic Search Filters 32 OP24 Challenges Of Translating Search Filters Between Different Interfaces 33 OP25 Organisational Learning Principles Applied To Information Retrieval 33 OP26 Search Approaches In Information Retrieval Presented In HTAi SuRe Info 34 OP27 Engaging Patients: The EuroCAB Programme 35 OP28 Patient Involvement At AQuAS: Experiences And Reflections For Future 36 OP29 Building A Global, Public Repository Of Patient Experience Data 37 OP30 Impact Of Patient Reported Outcomes Data On HTAs In AML 38 OP31 HTA And Patients’ Preferences: Starting A Discrete Choice Experiment 39 OP32 Stakeholder Requirements For Real-World Drug Utilization Evidence 40 OP33 Treatment Of Mitral Insufficiency And Multicriteria Decision Making 41 OP34 One-Way Sensitivity Analysis For Cost-Effectiveness Analysis 42 OP35 A Framework For Economic Evaluations With Interactions Between Groups 42 OP36 The Probabilistic Incorporation Of Structural Uncertainty In Models 43 OP37 Impact On Uncertainty Of Disaggregating Cost Data 44 OP38 Implementing Social Innovations: From Evidence-Based To Theory-Driven 45 OP39 Adapting HTA To Suit Emerging Needs - An Australian Experience 46 OP40 Criminal Justice Costs And Benefits Of Mental Health Interventions 47 OP41 Intercultural Medical Decision Support System Using NLP 48 2 HTAi 2019 ANNUAL MEETING • ABSTRACTS BOOK OP42 Updated Qualitative Syntheses: What Can They Offer To HTA? 50 OP43 Sourcing Professional Advice: Striving For Consistency 51 OP44 Robot-Assisted Surgery: Joint HTA To Inform Australian Policy And Fund 51 OP45 Biological Drugs And Rheumatoid Arthritis In Brazil: An Overview 52 OP46 Evaluating Statin Utilisation In The NHS Scotland 53 OP47 Need For New Thrombectomy Centres? A Practical Decision Framework 55 OP48 Nursing Requirements In Long-Term Care: A Health Technology Assessment 56 OP49 MAIC-ing Use Of Trials? Study Of Matching Adjusted Indirect Comparison 57 OP50 IQWiG And GRADE – An Exemplary Comparison Of Methods 57 OP51 Comparison Of The Measurement Properties Of The PROBE And EQ5D On Pain 58 OP52 Use Of Intention To Treat And Magnitude Of Treatment Effects 59 OP53 HTA Acceptability Of Innovative Survival Metrics In Oncology 60 OP54 Monitoring Evidence On Overall Survival Benefits Of Anti-Cancer Drugs 61 OP55 Effects Of Regulatory Major Objections On Reimbursement Decisions 62 OP56 Are TPRs Driving Pharmaceutical Reimbursement Outcomes In Spain? 63 OP57 Threats And Opportunities To Digital Health In Primary Care 64 OP58 Developing An Evaluation Based Taxonomy For mHealth Apps 65 OP59 HTA Of A mHealth App For Young People With Diabetes 65 OP60 Challenges In Evaluating Smart Medical Devices 66 OP61 Data From Smart Devices: The Apple Watch And Atrial Fibrillation 67 OP62 Let’s Co-Design A Tool To Assess Overweight And Obesity Health Apps 68 OP63 Clinical Videoconferencing - Critical-Realist Review As Evidence? 69 OP64 Implementation Of Whole Exome Sequencing For Rare Diseases 70 OP65 Health Technology Assessment Of Orphan Drugs: Impact Of Extra Criteria? 71 OP66 Cost Of Direct Import Unlicenced And Orphan Medicines In Turkey 72 OP67 A Composite Model For Pricing New Orphan Drugs 72 OP68 Value-Engineered Translation: An Example For Bladder Cancer Diagnosis 73 OP69 Initiatives To Improve The Timeliness Of Cancer Diagnosis 74 OP70 Aligning Value In Regulatory And Health Technology Assessments 75 OP71 Understanding Hospitals’ Performance Variability: Conceptual Framework 76 OP72 HTA Beyond 2020 In China: HB-HTA Rising Up In Tertiary Hospitals 77 OP74 Stoma Cover Use By Fully Laryngectomized Patients 78 OP75 Facts And Values In HTA: The Case Of Non-Invasive Prenatal Testing 79 OP76 HTA And The Right To Health Care: Lessons From South Africa 80 OP77 Nudging In NIPT: Ethical Guidance 81 OP78 Picturing ELSI+: Mapping Ethical, Legal, Social And Value Issues 82 OP79 Improving Public Understanding Of Scottish Medicines Consortium Advice 83 OP80 Impact Of Patient Group Participation At SMC Committee Meetings 83 OP81 Building Technical Capacity To Promote Patient Involvement In HTA 84 OP82 An Economic Evaluation Of Mobile Messages Aided Smoking Cessation In [...] 85 OP83 Iterative Formative Research Informing Primary Care Education Design 86 OP84 Collaborative Program To Improve Early Management Rheumatoid Arthritis 87 HTAi 2019 ANNUAL MEETING • ABSTRACTS BOOK 3 OP85 Persistence Leads To Ongoing Decreases In Primary Care Antibiotic Use 88 OP86 Exploring Public Utilisation Data For Primary Care Education Programs 89 OP87 A Conceptual Analysis Of QoL Measures: Ethical Implications For HTA 90 OP88 Digital Approaches For RCT Recruitment Or Retention: A Systematic Map 91 OP89 Conference Abstract Searching In NICE Health Technology Appraisals 92 OP90 Robotic Surgery’s Value: When The Evidence ‘Fuels’ The Controversy 92 OP91 Developing A Celtic Connections Regional HTA Alliance 93 OP92 One Size Fits All? Will EU Cooperation On Assessments Improve HTA? 94 OP93 Collaboration Between HTA And Procurement: A Rapid Mixed-Methods Study 95 OP94 Surrogate Endpoints In HTA: A Methods Guidelines Review Across Europe 96 OP95 Patient Reported Outcome Measures In Health Technology Decision Making 97 OP96 Assessing Impact Of UK Health Technology Assessment Programme Trials 98 OP97 Cost-Effectiveness Model Appraisal Guidelines For HTAs In Ireland 99 OP98 Limitations In Health-Economic Guidance For Medical Devices 100 OP99 Musings On Equity, Opportunity Cost And Health Economic Evaluation 101 OP100 Cost-Effectiveness Analysis: Based On Real-World Data From China 101 OP101 Is Lung Cancer Screening Cost Effective? A Systematic Review 102 OP102 How To Invest In Getting Cost-Effectiveness Screening Into Practice? 103 OP103 Incorporating HTA In The Development Of A Clinical Care Pathway 104 OP104 Hospital-Based Health Technology Assessment In China 105 OP105 Factors Affecting Horizon Scanning For Hospital-Based HTA 106 OP106 The Xpert™ C. Difficile Kit In The Hospital Health Technology Assesmen 106 OP107 Transition From Conventional Pathology Lab To Digital Lab: A Mini-HTA 107 OP108 Association Of Shared Decision Making With Patient Satisfaction 108 OP109 The Need For Building Pharmacists HTA Capacity; The Nigerian Scenario 109 OP111 Trends In National Health Insurance Enrolment In Ghana 110 OP112 Project Management In EUnetHTA Non-Pharmaceutical Technologies 111 OP113 The META Tool: Helping Medtech Developers To Understand HTA 112 OP114 Towards Common Understanding Of HTA Education And Training Programs 113 OP115 Expanding Perspectives: The Role Of Environmental Scanning In HTA 113 OP116 Horizon Scanning Influence In Incorporation Of Biologics For Psoriasis 114 OP117 Optimising Horizon Scanning For New Medicines Using Machine Learning 115 OP118 Capability Of Opinion Leaders In HTA: Public Involvement In Korea 116 OP119 Reimbursement Decisions In The Netherlands – A Citizen Panel 117 OP120 Changing Views: Qualitative Results From A Deliberative Citizen Panel 118 OP121 High Risk High Complexity and Cost Devices Hospital-Based Management Impact 119 OP122 Resource Use Measurement Issues: A Scoping Review 120 OP123 A Cost-Effectiveness Registry For Prioritization In Emerging Markets 120 OP124 Disinvestment – A Global Challenge Requiring Collaboration? 121 OP125 Disinvestment Activities And Candidates In The HTA Community 122 OP126 RWD Supplements Evidence To Update UK Commissioning Policy 123 OP127 Sugar And Spice And All Things NICE Managed Access Agreements 124 4 HTAi 2019 ANNUAL MEETING • ABSTRACTS BOOK OP128 Extracorporeal Membrane Oxygenation: A Six-Year Real-World Evaluation 125 OP129 Healthcare Utilization After Bariatric Surgery 126 OP130 Evidence-Informed Policy For Biologic Medicines In Brazil 127 OP131 Rapid Review For Policy: Interchangeability Of Biological Medicines 127 OP132 What Future For Drugs After An Early Dialogue Procedure?